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time-dependent adverse effects such as myopathy, growth retardation, metabolic disturbances, and osteoporosis (Saag et al., 1994) . Owing to the chronic nature of RA, long-term steroid treatment remains common and necessary for alleviation of active disease activity. As a result, the undesired effects that are commonly associated with long-term and high dose steroid therapy have a profound influence on the health-related quality of life of RA patients.
The NSAIDs are widely prescribed drugs for their potent analgesic, antipyretic and antiinflammatory properties. Their pharmacological effects are mainly attributed to inhibition of cyclooxygenase (COX) and the consequential decreased synthesis of pro-inflammatory PG, thereby reducing pain and inflammation and improving physical function (Ricciotti and FitzGerald, 2011; Crofford, 2013) . Naproxen (NPX), a non-selective COX inhibitor, has been extensively used in the symptomatic management of RA. It shows balanced inhibitory potencies on both COX isoforms, constitutive COX-1 and inflammation-inducible COX-2 (Vane, 1971) . NPX is better tolerated with respect to common adverse effects associated with NSAIDs (e.g. gastrointestinal bleeding and potential cardiovascular toxicity) compared to COX-selective NSAIDs (Lussier et al., 1978; Watson et al., 2002) . However, like other NSAIDs, NPX is not disease modifying when used alone, thus providing the basis for its frequent use in combination therapy for RA.
Combination therapy has now become standard practice in treatment of RA. In view of the shared pharmacological effects of DEX and NPX in inhibiting the factors promoting disease production, we hypothesize that their joint use might permit dose reduction of DEX, thereby reducing side effects without compromising efficacy. The current work aims to assess the individual and joint pharmacodynamic (PD) effects of DEX and NPX through both in vitro and in vivo studies. Their combined immunosuppressive action was first evaluated by the in vitro inhibition of concanavalin A (Con A)-stimulated whole blood lymphocyte proliferation (WBLP). The pharmacokinetics (PK) of DEX in female and male healthy rats, the PK of NPX after coadministration of DEX, and the effects of NPX and DEX in collagen-induced arthritic (CIA) rats of both sexes were examined. Mathematical models incorporating a dual interaction equation were DMD # 75614 9 2, 3, 4, 6, 8, 12 , 24 h and processed and analyzed for DEX by a liquid chromatography-tandem mass spectrometry (LC-MS/MS) method used previously (Samtani and Jusko, 2007) with slight modifications. Briefly, 100 μL 4% phosphoric acid was added to 100 μL of plasma and then spiked with 10 μL of Internal Standard (IS) working solution. The mixture was vortex-mixed and centrifuged at 13000 ×g for 10 min at 10°C and then subjected to solid phase extraction. The dried residue was reconstituted with 200 μL acetonitrile-water (50:50, v/v) followed by vortexing and centrifugation at 13000 ×g for 10 min at 10°C. The supernatant was transferred into vials and used for LC-MS/MS injection. Chromatographic separations were achieved on a C8 Hydrobond AQ Column (particle size 3 μm, 150 × 2.1 mm; MAC-MOD Analytical Inc., Chadds Ford, PA) with the column oven temperature set at 30°C. The mobile phase consisted of eluent A (water containing 5 mM ammonium formate and 0.1% formic acid) and eluent B (acetonitrile/water (95:5 v/v) containing 1 mM ammonium formate and 0.1% formic acid) and was pumped at a flow rate of 0.2 mL/min with a gradient elution. The gradient profile was: 0 min, 40% B; a linear increase to 70% B from 0 to 2 min; 70% B for 3 min; a linear increase to 95% B over 0.1 min; 95% B for 1.9 min; a linear decrease to 40% B from 7 min to 7.1 min; 40% B for 3.9 min and stop at 11.0 min.
The mass spectrometer was operated in the positive ionization mode for the detection of ion transitions at m/z 393.3/373.3 for DEX and 398.5/378.6 for IS. The system was controlled by Analyst software version 1.4 (Applied Biosystems SciEx, Toronto, Canada) for data acquisition and analysis.
The NPX concentrations in combined dosing groups were compared with those in single drug groups to assess the influence of single-dose DEX on the PK of NPX. Serial blood samples were collected from the saphenous vein at 15, 30 and 45 min and 1, 2, 4, 6, 9, 12, 24 h and analyzed for NPX by LC-MS/MS (Li et al. 2017a ).
Linearity was found over the concentration ranges of 0.2 to 100 ng/mL for DEX and 0.125 to 40 µg/mL for NPX. For both bioanalytical assays, the coefficient of variation (CV%) of intraThis article has not been copyedited and formatted. The final version may differ from this version. and inter-day accuracy and precision were less than 15%, and the recovery of the sample preparation method was around 90% for DEX and approached 100% for NPX.
Pharmacokinetic Models. The plasma concentration-time profiles of NPX were described by an extended minimal physiologically based pharmacokinetic (mPBPK) model with plasma and one tissue compartment (Figure 1) . Detailed model descriptions and assumptions are provided in (Li et al, 2017b) . The model equations and initial conditions are:
where , indicates the amount of NPX at the absorption site, , is the first-order absorption rate constant, , and are total NPX concentrations in (plasma volume) and (ISF volume), is cardiac plasma flow, , is the fraction of drug in accessing , is clearance of unbound NPX from plasma, and , are the unbound NPX concentrations in plasma and ISF that could be calculated from their corresponding total concentrations using the equations, albumin concentrations and binding parameters provided in (Li et al, 2017a , Li et al, 2017b , and is the bioavailability of the IP dose calculated to be about 0.9 from literaturereported intravenous data in rats (Lauroba et al., 1986) . The physiological restrictions of relevant parameters are:
, ≤ 1 and + = Extracellular Fluid Volume (ECF = 206.29 mL/kg) (Shah and Betts,
2012)
The plasma concentration-time profiles of DEX after 2.25 mg/kg SC injection to female and male healthy rats were characterized by the basic mPBPK model (Cao and Jusko, 2012) shown in Figure 1 . The model equations and initial conditions describing DEX PK are: The unbound fraction of DEX in ISF (f uISF ) was calculated using :
where E/P is the ratio of protein concentrations in ISF and plasma with a value of 0.9 used for arthritic rats (McNamara et al., 1983 , Li et al., 2017a .
The PK of DEX in rats was found to be linear with dose and not affected by RA (Samtani and Jusko, 2005; Earp et al., 2008c) ; therefore, the PK parameters obtained by fitting the PK data of 2.25 mg/kg of SC DEX in healthy rats were used to simulate the total tissue concentrations of DEX ( ) in arthritic rats that received 0.225 mg/kg of SC DEX. The unbound DEX concentrations in ISF ( , ) were then generated from ,
• .
Pharmacodynamic Models
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where is the CPM in the presence of drug, is the baseline CPM in the absence of drug, is the maximum effect achieved by either drug, is the drug concentration at 50% of maximum inhibition, is the total concentration of NPX or DEX in the culture medium, and is the Hill coefficient for the immunosuppressive effect. All model parameters were fitted to the CPM values for each of the four wells of each drug concentration.
The combined inhibitory effects of the two drugs on lymphocyte proliferation were characterized by a joint interaction model (Chakraborty and Jusko, 2002 ). The published model was modified to allow for the estimation of actual CPM values instead of normalized CPMs.
• 1 , •
where φ is the interaction term for lymphocyte proliferation inhibition where values of 1 indicate no interaction, less than 1 synergism, and greater than 1 antagonism.
Single and Combined Drug Effects in Rat Arthritis. Figure 1 depicts a general model scheme for the entire arthritis progression with the anti-inflammatory effects of NPX and DEX acting on paw edema production. The PK/PD model structure for the single drug effects of NPX was presented in (Li et al. 2017b ). In this model, we assumed that the paw size increase in healthy rats follows logistic growth. Therefore, before disease onset the rate of change of the paw volume over time in all groups is:
where is the sum of ankle and paw cross-sectional areas of a rat hind foot; is the normal paw size at steady-state, is the natural first-order growth rate constant of paw in healthy rats, and is the time delay observed before disease onset.
After disease onset, the paw volume-time profiles in the control group with no drug are:
where is a function of time and represents the production of paw edema after disease onset; is a linear decline in accounting for the natural remission of arthritis; and is the first-order rate constant describing the loss of edema.
Based on the mechanisms of drug action, indirect response model I (IDR I) was applied to describe the individual inhibitory effects of NPX and DEX on paw edema production (Dayneka et al, 1993) . The rate of change of paw size over time for a single drug were described as:
where is the maximum inhibition effect of either NPX or DEX on production of paw edema and is the unbound ISF concentration ( ) of drug required for 50% of maximal effect.
The combination effects of NPX and DEX were characterized using a dual drug inhibition approach (Earp et al., 2004) . The paw size change over time in combined treatment groups is:
This article has not been copyedited and formatted. The final version may differ from this version. where Ψ 2 is the interaction term for inhibition of paw edema production as defined for Eq 9. The model assumes that the drugs inhibit the pro-inflammatory processes (k in ) as directly demonstrated for DEX by Earp et al (2008b) . Values of I max and IC 50 for each drug were generated from their individual studies allowing Ψ 2 to be resolved from the studies with joint NPX and DEX administration.
Model Fitting and Data Analysis. Naïve-pooled data from all replicates in the WBLP assay were analyzed jointly. Initial non-compartmental analysis (NCA) of the PK data of NPX and DEX was performed using Phoenix WinNonlin 6.4 software (Certara Corporation, Princeton, NJ).
All PK data for NPX from our previous study (Li et al., 2017a) and this study were fitted jointly as well as DEX PK data for both sexes. The obtained PK parameter estimates were fixed in the subsequent PD analysis in CIA rats. All model fittings involved nonlinear regression using the Table 2 . Both NPX and DEX produced complete suppression of cell proliferation and thus both I max values were fixed to 1.0. The IC 50 of NPX for WBLP was estimated to be 83.97 µg/mL, which is slightly lower than reported for human lymphocytes (350 µg/mL) (Panush, 1976) . It is very close to the peak plasma concentration (79 µg/mL) achieved in RA patients after 500 mg twice daily doses of NPX (van den Ouweland et al., 1987) . This is in accordance with previous findings that the anti-proliferative effects of NSAIDs often occur at doses/concentrations high enough to suppress inflammatory responses (Seng and Bayer, 1986) .
DEX was more efficacious in suppressing lymphocyte proliferation than NPX as indicated by the 5-fold difference in their log IC 50 values. The estimated IC 50 value of DEX (1.5 ng/mL) is comparable to that using human whole blood culture (3.8 ng/mL) (Mager et al., 2003) , which suggests that the anti-proliferative effect and sensitivity of the mitogenic response of lymphocytes to DEX are similar across species. The Hill coefficient was 3.04 for DEX, similar to that for NPX (2.92). The fittings included baseline CPM values for complete assessment of all parameters with potential variability. The combination effects of NPX and DEX on lymphocyte proliferation was evaluated using 20 concentration combinations. These data were fitted using the joint interaction model (Eq. 9) where the interaction term Ψ was factored with the IC 50 of DEX because the primary immunosuppressive effects were exerted by DEX. A three-dimensional surface plot ( Figure 2C) shows the combined drug effects on lymphocyte proliferation, where the surface represents the model predictions using Eq. 9 based on the estimated parameters in Pharmacokinetics of NPX and DEX in CIA Rats. The pharmacokinetics of NPX in the combined treatment groups was compared with that in the single drug groups from our previous study (Li et al., 2017a) . The concentration-time profiles of NPX in CIA rats after giving 50 mg/kg NPX alone or together with 0.225 mg/kg DEX along with the model fittings and calculated total and unbound ISF NPX concentrations are illustrated in Figure 3 . The NCA results for the primary PK parameters of NPX including area under the concentration-time curve (AUC), apparent clearance (CL/F), apparent volume of distribution (V/F), and terminal half-life (t 1/2 ) are listed in Table 3 . No obvious visual differences are seen for the PK profiles and also no significant differences in the PK parameters was found, suggesting that single-dose DEX did not affect the PK of NPX in CIA rats. Therefore, the PK parameter estimates of NPX obtained using the NCA results for the primary PK parameters of DEX indicates that the terminal half-life (t 1/2 ) of DEX is significantly shorter in males (Table 3) , thus different clearance terms (CL p ) were assigned to female and male rats in the model. The mPBPK model was able to capture all the PK data of DEX in healthy rats quite well ( Figure 4 ) and yielded precise parameter estimates with reasonable CV% values ( The estimated tissue partition coefficient (K p ) is 0.63, which is close to those calculated from the steady-state distribution volume (V ss /BW = 0.7) and a literature-reported estimation method (0. (Table 5 ). The disease-specific parameter estimates for male arthritic rats are comparable to those reported previously (Earp et al., 2009; Lon et al., 2011) .
In general, the paw edema RA progression of female and male arthritic rats in the present study showed similar patterns and trends with those obtained previously (Li et al, 2017b) , where females exhibited higher incidences (80% vs 60%), earlier disease onset (t onset , 258 vs 307 h), faster disease production rate (group-averaged k in0 , 2.02 vs 1.78 mm 2 /h), and more severe symptoms. In the absence of drug, paw size changes over time before disease onset were assumed to follow the logistic growth function (Eq. 11) and increased at the same rate as in healthy animals (the estimated k g was 0.002 h -1 for both sexes).
The individual anti-inflammatory effects of NPX and DEX were characterized using Eq. 13.
NPX was previously found to be more efficacious in male arthritic rats as demonstrated by the maximum inhibitory effect ( , , 1.0 vs 0.75 for females) and concentration for 50% maximal effect ( , , 136 vs 221 ng/mL) (Li et al, 2017b) . A pilot study assessing the effects of two single SC doses of DEX (0.225 and 2.25 mg/kg) on paw edema in female and male CIA rats was conducted (unpublished) and the paw edema data were described by the mPBPK/PD/DIS progression model (Figure 1 ) using unbound ISF DEX concentrations as the driving force for PD.
Preliminary fittings revealed values of , that were 1.0 and thus it was set as 1.0 for both sexes. A lower , value of 0.39 ng/mL obtained for males than females (0.62 ng/mL) (Table   5 ) suggested that DEX exhibited modestly stronger potency in males consistent with the effects of NPX. The strong inhibition of paw edema observed for the combined treatment groups was satisfactorily described by the mPBPK/PD/DIS progression model incorporating the joint interaction equation (Eq. 14). During the model fitting, all drug-specific PD parameters (I max and IC 50 ) were fixed to the values listed in Table 5 with only the disease-specific parameters and interaction term Ψ 2 were estimated by simultaneously fitting all of the paw volume data from each sex group. The disease-related parameters were re-estimated to account for the between-batch variation of CIA animals. The interaction term Ψ 2 was found to be 1.16 (confidence interval 0.49- 
Discussion
Corticosteroids have long been the mainstay of RA therapy owing to their potent immunosuppressive and anti-inflammatory actions. However, the clinical effectiveness of DEX and other CS is compromised by their long-term and dose-related adverse effects. We extended our previous PK/PD studies with NPX (Li et al, 2017a (Li et al, , 2017b and DEX (Earp et al, 2008a (Earp et al, , 2008b (Earp et al, , 2008c ) to investigate whether better therapeutic outcomes could be achievable by a combination of DEX and NPX and to ascertain whether sex differences exist.
First, the single and combined immunosuppressive actions of DEX and NPX were evaluated by the In vitro WBLP assay, which measures the mitogenic response of T lymphocytes to drugs. This assay is convenient to assess the nature and intensity of drug-drug interactions as it mimics the natural milieu and requires small blood volumes. The relative immunosuppressive potency of several therapeutic CS were studied previously using this assay (Mager et al., 2003) .
DEX inhibits T lymphocyte proliferation by suppressing NF-kB causing reduction of IL-2 gene
expression, which is responsible for the proliferation and differentiation of T lymphocytes (Toribio et al., 1989) . Insufficient attention has been paid to the immunologic actions of NSAIDs, although considerable evidence has shown their capability of suppressing lymphocyte activation (Kelly et al., 1979; Ali et al., 1984; Seng et al., 1990; Cicala et al., 2000) . The commonly acknowledged mechanism of action of NSAIDs is to block the synthesis of PG via COX inhibition. However, PG were reported to inhibit the mitogen-induced proliferation of T cells (Goodwin et al., 1977) .
Therefore, the anti-proliferative effect of NSAIDs may involve COX-independent mechanisms.
These drugs have been shown to inhibit DNA synthesis and cause cell growth arrest in the G1 phase (Bayer and Beaven, 1979) . The nature and intensity of interactions between DEX and NPX on lymphocyte proliferation were evaluated. The slightly synergistic effect of NPX on the antiproliferative action of DEX (Ψ 1 < 1) is promising in that combination therapy would add to and possibly potentiate the immunosuppressive activity of DEX.
This article has not been copyedited and formatted. The final version may differ from this version. To further examine the PD interactions between DEX and NPX, the joint anti-inflammatory effects of DEX and NPX was investigated in vivo using CIA rats, a well-established animal model that mirrors human RA (Holmdahl et al., 2001 ). Similar to humans, the CIA rat model exhibits consistent sex differences in the disease progression of arthritis in that females exhibit higher incidences, earlier disease onset, and worse symptoms. We used this animal model previously to assess the PK/PD of both NPX (Li et al., 2017b) and DEX (Earp et al., 2008a) . NPX exhibited moderate but significant inhibitory effects on paw edema production in both sexes with slightly stronger efficacy in male rats, and DEX showed potent anti-inflammatory effects in male arthritic rats with 60% reduction of paw edema compared to untreated controls. In particular, DEXdependent trans-repression of production of the cytokines TNF-α, IL-1β, and IL-6 plays a central role in the alleviation of paw edema and bone erosion in arthritic rats (Earp et al., 2008a) .
Both female and male CIA rats were studied so that the influence of sex in the antiinflammatory actions of DEX with NPX could be compared. The proposed PK/PD/DIS progression model (Figure 1 ) well characterized the anti-inflammatory effects of DEX and NPX both as single agents and in combination. The PK models include an extended mPBPK model with nonlinear binding for NPX adapted from our previous study (Li et al., 2017b) and a basic mPBPK model for DEX. The individual drug effects described by the inhibition model was linked to the calculated unbound ISF concentrations of both NPX and DEX. This was done for several reasons. As shown previously (Li et al., 2017b) , the unbound NPX concentration-time profiles in ISF closely resembled those in synovial fluid (SF), which better correlate with the clinical efficacy of NPX as the synovium is the proposed site of action in RA (Jalava et al., 1977; Netter et al., 1989; Bertin et al., 1994; Day et al., 1995) . DEX must permeate cells to bind to receptors and/or alter transcriptional factors, thereby exerting its effects. Rapid equilibration of unbound DEX concentrations between plasma, ISF, and cell water was thus assumed. According to their corresponding mechanisms of action, the joint effect of DEX and NPX was exerted on the production process of paw edema in a joint and noncompetitive manner and therefore modeled using the dual drug inhibition approach (Chakraborty and Jusko, 2002; Earp et al., 2004) .
The hepatic metabolism of NPX is mainly mediated by cytochrome P450 (CYP) 1A2 and 2C9 (Miners et al., 1996) , which were reported to be induced by DEX in vitro (Gerbal-Chaloin et al., 2002; Vrzal et al., 2009 ). The NCA results for the primary PK parameters of NPX with or without joint dosing of DEX (Table 3) indicated that the single-dose of DEX had no significant influence on the PK of NPX in either female or male CIA rats. Previous studies have shown that the PK of DEX in CIA male rats was not altered by RA (Earp et al., 2008c) and DEX concentrations in healthy male rats after SC and IM dosing were shown to be identical (Earp et al., 2008a) . The same situation was assumed here for female rats and thus DEX PK in healthy rats was used to model the PK in arthritic rats. In addition, the PK parameters after IM dosing of DEX in female rats were found to be in good agreement with those in males with 86% bioavailability for both sexes (Samtani and Jusko, 2005) . We also assumed that the PK of DEX was not altered by NPX.
Therefore, the same PK parameter values of DEX were applied for both single and combined drug groups. Male arthritic rats exhibited better responses to NPX, which can be partially explained by the higher unbound ISF concentrations of NPX (Li et al, 2017b) . A similar sexspecific response was observed for DEX, consistent with previous findings that the antiinflammatory actions of CS are more effective in males because they have more glucocorticoidresponsive genes (Duma et al., 2010) . The IC 50 values of NPX in both sexes are close to the peak unbound NPX concentrations in synovial fluid (SF) after a single dose of 500 mg NPX to arthritic patients (0.13 µg/mL) (Day et al., 1995) , further confirming the feasibility of utilizing the unbound NPX concentrations in ISF/SF to mimic the biophase concentrations. In line with the in vitro results, DEX was more efficacious in reducing paw edema production in both sexes than NPX. For combination treatments in CIA rats, the interaction term Ψ 2 incorporated in the inhibition of paw edema production (Eq. 14) is similar to the Ψ 1 in Eq. 9, which reflects the magnitude by which the for male arthritic rats. The occurrence of additivity is sufficient to produce steroid-sparing effects.
The Ψ parameter is an empirical term that used to signify the nature of pharmacological interactions (synergic, additive or antagonistic) when detailed mechanisms are unclear. Further studies with the measurements of the molecular factors that drive chronic arthritis and that are relevant to the effects of DEX and NPX, such as the cytokines TNF-α, IL-1β, IL-6 and PGE 2 , are necessary to better understand the sex-specific anti-inflammatory actions and the underlying mechanisms of interaction.
Overall, the drug-specific parameters (I max and IC 50 ) of both drugs obtained in vivo were comparable to the in vitro values except that the maximum inhibition of NPX on paw edema in female arthritic rats was less than 1.0 (I max = 0.75). This difference is quite reasonable since the whole blood used in the in vitro study was from healthy male rats and, more importantly, drug effects in vivo incur many additional complicating factors. In our study, the PD models were directly fitted to the actual measured CPM and pooled paw volume data without normalization by the control data, thus avoiding the impact of the variability from control groups (Woo et al., 2009 ).
In conclusion, the single and joint effects of DEX and NPX on the in vitro mitogenstimulated proliferation of T lymphocytes and in assessing paw edema in female and male CIA rats were well described by mathematical models incorporating dual interaction equations for inhibition. With an interaction term Ψ, the proposed models also indicated the slight extent to which the potency (IC 50 ) of DEX is altered by NPX. Our study has thus mainly demonstrated additive immunosuppressive and anti-inflammatory effects of the drug combination. With the promising steroid-sparing potential of NPX, the combined use of DEX and NPX should permit dose reduction of steroids. The models may be useful to design preclinical studies with related drugs and devise clinical CS dosing regimens that maximize desired effects (immunosuppression and anti-inflammation) while minimizing unwanted effects in treatment of RA.
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